Biotech Values

[ciotera]

RE: BMY’s TYK2 inhibitor, Deucravacitinib is not affected

Also, because it doesn't yet have a label. Kind of early to speculate whether it'll be impacted or not. What is puzzling to me is that this class effect from Xeljanz has impacted the label of topical ruxolitinib but not of oral ruxolitinib (which is also a JAK).